Morepen Laboratories Limited (MOREPENLAB.BO)
INR 49.26
(3.05%)
INR 49.26
(3.05%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.45 Billion INR | 24.56% |
| 2022 | 3.58 Billion INR | -27.22% |
| 2021 | 4.91 Billion INR | 13.39% |
| 2020 | 4.33 Billion INR | 14.21% |
| 2019 | 3.79 Billion INR | 4.78% |
| 2018 | 3.62 Billion INR | 0.62% |
| 2017 | 3.6 Billion INR | 5.15% |
| 2016 | 3.42 Billion INR | -2.4% |
| 2015 | 3.51 Billion INR | 73.88% |
| 2014 | 2.01 Billion INR | 4.73% |
| 2013 | 1.92 Billion INR | -6.7% |
| 2012 | 2.06 Billion INR | -8.97% |
| 2011 | 2.27 Billion INR | -4.54% |
| 2010 | 2.37 Billion INR | 5.69% |
| 2009 | 2.24 Billion INR | -37.74% |
| 2008 | 3.61 Billion INR | -1.13% |
| 2007 | 3.65 Billion INR | -35.99% |
| 2006 | 5.7 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -8.47 Billion INR | -289.97% |
| 2023 Q4 | 4.45 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 4.05 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 4.45 Billion INR | 24.56% |
| 2022 FY | 3.58 Billion INR | -27.22% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 3.58 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 3.15 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 4.91 Billion INR | 13.39% |
| 2021 Q2 | 5.46 Billion INR | 0.0% |
| 2021 Q4 | 4.91 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 FY | 4.33 Billion INR | 14.21% |
| 2020 Q2 | 4.56 Billion INR | 0.0% |
| 2020 Q4 | 4.33 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q2 | 4.23 Billion INR | 0.0% |
| 2019 Q4 | 3.79 Billion INR | 0.0% |
| 2019 FY | 3.79 Billion INR | 4.78% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q4 | 3.62 Billion INR | 0.0% |
| 2018 FY | 3.62 Billion INR | 0.62% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 3.62 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q1 | - INR | 0.0% |
| 2017 FY | 3.6 Billion INR | 5.15% |
| 2017 Q4 | 3.6 Billion INR | 0.0% |
| 2016 FY | 3.42 Billion INR | -2.4% |
| 2015 FY | 3.51 Billion INR | 73.88% |
| 2014 FY | 2.01 Billion INR | 4.73% |
| 2013 FY | 1.92 Billion INR | -6.7% |
| 2012 FY | 2.06 Billion INR | -8.97% |
| 2011 FY | 2.27 Billion INR | -4.54% |
| 2010 FY | 2.37 Billion INR | 5.69% |
| 2009 FY | 2.24 Billion INR | -37.74% |
| 2008 FY | 3.61 Billion INR | -1.13% |
| 2007 FY | 3.65 Billion INR | -35.99% |
| 2006 FY | 5.7 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 72.595% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 97.07% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | 13.919% |
| Granules India Limited | 22.95 Billion INR | 80.571% |
| Indoco Remedies Limited | 10.34 Billion INR | 56.878% |
| Achyut Healthcare Limited | 2.01 Million INR | -221449.379% |
| Ajanta Pharma Limited | 10.71 Billion INR | 58.36% |
| Alkem Laboratories Limited | 48.6 Billion INR | 90.824% |
| Alpa Laboratories Limited | 307.12 Million INR | -1352.123% |
| Brooks Laboratories Limited | 248.6 Million INR | -1693.955% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -21.815% |
| Bajaj HealthCare Limited | 4.86 Billion INR | 8.379% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -111.48% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 95.831% |
| Eris Lifesciences Limited | 38.26 Billion INR | 88.346% |
| FDC Limited | 3.7 Billion INR | -20.236% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 93.15% |
| Gufic Biosciences Limited | 5.59 Billion INR | 20.358% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -94.796% |
| Ipca Laboratories Limited | 33.74 Billion INR | 86.783% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -1402.827% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -49.964% |
| Lasa Supergenerics Limited | 541.92 Million INR | -722.953% |
| Laurus Labs Limited | 42.71 Billion INR | 89.559% |
| Lupin Limited | 96.23 Billion INR | 95.366% |
| Mankind Pharma Limited | 23.87 Billion INR | 81.32% |
| Medicamen Biotech Limited | 940.36 Million INR | -374.26% |
| Medico Remedies Limited | 438.24 Million INR | -917.65% |
| Megasoft Limited | 1.85 Billion INR | -140.661% |
| NATCO Pharma Limited | 10.53 Billion INR | 57.655% |
| Piramal Pharma Limited | 74 Billion INR | 93.974% |
| RPG Life Sciences Limited | 1.38 Billion INR | -223.126% |
| Sigachi Industries Limited | 2.53 Billion INR | -76.188% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 97.571% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -119.237% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -282.745% |
| Unichem Laboratories Limited | 8.06 Billion INR | 44.731% |
| Wanbury Limited | 3.15 Billion INR | -41.333% |
| Windlas Biotech Limited | 1.76 Billion INR | -153.009% |
| ZIM Laboratories Limited | 2.08 Billion INR | -114.334% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 93.788% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -14.562% |
| Divi's Laboratories Limited | 18.99 Billion INR | 76.515% |
| Hester Biosciences Limited | 3.59 Billion INR | -24.065% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -74.129% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -468.978% |
| Bal Pharma Limited | 2.51 Billion INR | -77.591% |
| Strides Pharma Science Limited | 37.68 Billion INR | 88.164% |
| Venus Remedies Limited | 1.39 Billion INR | -220.203% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 45.947% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 60.245% |
| Shilpa Medicare Limited | 12.93 Billion INR | 65.515% |
| Aarti Drugs Limited | 11.5 Billion INR | 61.233% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 29.533% |
| Suven Life Sciences Limited | 148.62 Million INR | -2900.78% |
| Ind-Swift Limited | 13.45 Billion INR | 66.849% |
| Valiant Laboratories Limited | 1.05 Billion INR | -321.427% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 58.351% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | 68.468% |
| Themis Medicare Limited | 1.88 Billion INR | -136.279% |
| Hikal Limited | 12.99 Billion INR | 65.68% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 94.565% |
| Sequent Scientific Limited | 8.27 Billion INR | 46.1% |
| Novartis India Limited | 1.8 Billion INR | -147.615% |
| Wockhardt Limited | 39.87 Billion INR | 88.814% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 92.722% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -1444.254% |
| Neuland Laboratories Limited | 5.49 Billion INR | 18.892% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -592.64% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -125.662% |